In vitro study | CP-673451 is a selective PDGFR α/β inhibitor with an IC50 value of 10 nM/1 nM, which is more than 450 times more selective than other angiogenic receptors. In malignant glial tumors, CP-673451 (33 mg/kg) was able to inhibit> 50% of the PDGFR-β receptor for 4 H, with a corresponding EC50 of 120 ng/mL at C max in plasma. In the angiogenesis model of sponges, CP-673451 at 3 mg/kg (q.d. × 5, p.o., at a dose of 5.5 ng/mL at C max), 70% PDGF-BB-stimulated angiogenesis was inhibited. CP-673451 reduces cell proliferation by reducing phosphorylation of GSK-3α and GSK-3β. In RD and RUCH2 medium, CP-673451 interferes with rhabdosphere formation ability and cell differentiation, resulting in increased senescence. |
In vivo study | CP 673451 (once daily oral dosing) inhibits a number of human transplanted tumors in athymic mice, including H460 human lung carcinoma, Colo205 and LS174T human colon carcinoma, and U87MG human glioblastoma, in its subcutaneous growth (ED50 < 33 mg/kg). In RUCH2 xenografted mice, CP 673451 reduced tumor growth and stromal cell infiltration. |